View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDeinove 향후 성장Future 기준 점검 2/6핵심 정보77.4%이익 성장률74.80%EPS 성장률Chemicals 이익 성장11.2%매출 성장률97.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트31 Oct 2022최근 향후 성장 업데이트Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.모든 업데이트 보기Recent updatesBreakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 08First half 2022 earnings releasedFirst half 2022 results: Net loss: €3.56m (loss widened 13% from 1H 2021). Revenue is forecast to grow 201% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Chemicals industry in France.공시 • May 20Deinove SA, Annual General Meeting, May 30, 2022Deinove SA, Annual General Meeting, May 30, 2022, at 15:00 Central European Standard Time. Location: 48 rue Cambon Paris FrancePrice Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.Reported Earnings • Apr 14Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Net loss: €6.96m (loss narrowed 4.7% from FY 2020). Revenue exceeded analyst estimates by 19%. Over the next year, revenue is expected to shrink by 33% compared to a 22% growth forecast for the industry in France.공시 • Apr 08Deinove SA Announces the Extension of Its Clinical Trial to CanadaDeinove SA announced the extension of its clinical trial to Canada, approved by the Canadian Health authority, with the opening of 5 new sites, complementing those already opened in the United States. This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections. The second part of the study will be conducted in an open-label manner. Thus, all 40 patients who will be included in the trial will receive DNV3837. As a reminder, the second part of the trial has been optimized with a reduction in the dose and duration of intravenous administration to 6 hours per day during the 10-day treatment period. This modification simplifies the management of the trial for the investigating physicians and their teams. More than 40% of hospitalized patients with Clostridioides difficile infection (CDI) have been classified as severe disease associated with higher morbidity and mortality1. The Centers for Disease Control and Prevention (CDC) identifies CDI as one of the leading causes of hospital-acquired infections, ahead of even MRSA2 infections. In the United States, it is estimated that CDI causes nearly half a million disease cases each year, and approximately 29,300 deaths3. This condition is not limited to the United States and recent studies4 show that the incidence of this type of infection is greatly underestimated in other parts of the world, such as Europe and Asia. To date, there is no proven therapeutic solution for CDI patients with severe vomiting, ileus and toxic megacolon. The oral route being compromised, the available treatments, which are mostly oral, have difficulty reaching the intestine because of the patient's pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously do not cross the gastrointestinal barrier and therefore do not reach the infection site. DNV3837 – a prodrug5 of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff. It has demonstrated significant activity and superiority to reference treatments against isolates of C. diff., regardless of their virulence (including the hyper virulent BI/NAP1/027 strain). DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approximately a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status.공시 • Jan 07Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile InfectionsDEINOVE announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI). The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial. The experience acquired during this first part of the study has made it possible to improve the trial protocol, with a reduction in dose by a factor of 4 and a reduction in the duration of administration by a factor of 2, reducing the intravenous treatment from 12 to 6 hours per day. This improvement simplifies the management of the trial for the investigating physicians and their teams. The second part of the study will be conducted in an “open-label” manner, as DNV3837 is administered intravenously, while the standards of care are administered orally. Thus, all patients included in the trial (40 in total) will receive DNV3837. To improve patients inclusion in the trial, it was decided to rapidly open new centers in addition to those active in the United States.Reported Earnings • Oct 03First half 2021 earnings releasedFirst half 2021 results: Net loss: €3.15m (loss narrowed 32% from 1H 2020).Reported Earnings • Mar 27Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €836.0k (up 49% from FY 2019). Net loss: €7.30m (loss narrowed 29% from FY 2019).공시 • Jan 22Deinove SA Appoints Hervé Ansanay as DirectorDeinove SA announces the strengthening of its Business Development team with the appointment of Hervé ANSANAY as Director and Corentin. The recruitment will intensify the implementation of profitable strategic partnerships and the access to non-dilutive financing, to support the development of antimicrobial therapeutic solutions. Hervé ANSANAY brings 20 years experience in accompanying innovative companies and in technology transfer. He was previously Technology Transfer and Business Development Director of the SATT AxLR of Montpellier where he also held the position of Chief Operating Officer.Is New 90 Day High Low • Jan 05New 90-day high: €0.91The company is up 50% from its price of €0.61 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Nov 26New 90-day high: €0.73The company is up 7.0% from its price of €0.68 on 28 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.58 per share.공시 • Nov 20Deinove SA Signs an Evaluation and Technology Development License with DSMDeinove SA announced the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living. Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.Is New 90 Day High Low • Oct 26New 90-day low: €0.54The company is down 30% from its price of €0.77 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.Reported Earnings • Oct 15First half earnings releasedOver the last 12 months the company has reported total losses of €9.52m, with losses narrowing by 8.2% from the prior year.이익 및 매출 성장 예측ENXTPA:ALDEI - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202421233112/31/202316-3-2-2112/31/20221-8-7-716/30/20220-7-7-7N/A3/31/20220-7-7-6N/A12/31/20211-7-6-6N/A9/30/20211-6N/AN/AN/A6/30/20211-6-6-6N/A3/31/20211-7-6-5N/A12/31/20201-7-5-5N/A9/30/20201-8N/AN/AN/A6/30/20201-10-4-4N/A3/31/20201-10-5-5N/A12/31/20191-10-7-6N/A9/30/20190-10N/AN/AN/A6/30/20190-10-10-9N/A3/31/20191-10-11-10N/A12/31/20181-9-11-10N/A9/30/20181-8N/AN/AN/A6/30/20181-8-9-7N/A3/31/20180-8-8-7N/A12/31/20170-7-8-7N/A9/30/20170-7N/AN/AN/A6/30/20171-6-8-7N/A3/31/20171-6-7-6N/A12/31/20161-6-6-5N/A9/30/20161-6N/AN/AN/A6/30/20161-7-5-5N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ALDEI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ALDEI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ALDEI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ALDEI 의 수익(연간 97.8%)이 French 시장(연간 5.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ALDEI 의 수익(연간 97.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ALDEI의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/04/08 21:30종가2023/01/10 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Deinove SA는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jonas PeciulisEdison Investment ResearchArnaud GuérinPortzamparc BNP ParibasPierre VauriceTPICAP Midcap
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.
Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 08First half 2022 earnings releasedFirst half 2022 results: Net loss: €3.56m (loss widened 13% from 1H 2021). Revenue is forecast to grow 201% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Chemicals industry in France.
공시 • May 20Deinove SA, Annual General Meeting, May 30, 2022Deinove SA, Annual General Meeting, May 30, 2022, at 15:00 Central European Standard Time. Location: 48 rue Cambon Paris France
Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.
Reported Earnings • Apr 14Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Net loss: €6.96m (loss narrowed 4.7% from FY 2020). Revenue exceeded analyst estimates by 19%. Over the next year, revenue is expected to shrink by 33% compared to a 22% growth forecast for the industry in France.
공시 • Apr 08Deinove SA Announces the Extension of Its Clinical Trial to CanadaDeinove SA announced the extension of its clinical trial to Canada, approved by the Canadian Health authority, with the opening of 5 new sites, complementing those already opened in the United States. This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections. The second part of the study will be conducted in an open-label manner. Thus, all 40 patients who will be included in the trial will receive DNV3837. As a reminder, the second part of the trial has been optimized with a reduction in the dose and duration of intravenous administration to 6 hours per day during the 10-day treatment period. This modification simplifies the management of the trial for the investigating physicians and their teams. More than 40% of hospitalized patients with Clostridioides difficile infection (CDI) have been classified as severe disease associated with higher morbidity and mortality1. The Centers for Disease Control and Prevention (CDC) identifies CDI as one of the leading causes of hospital-acquired infections, ahead of even MRSA2 infections. In the United States, it is estimated that CDI causes nearly half a million disease cases each year, and approximately 29,300 deaths3. This condition is not limited to the United States and recent studies4 show that the incidence of this type of infection is greatly underestimated in other parts of the world, such as Europe and Asia. To date, there is no proven therapeutic solution for CDI patients with severe vomiting, ileus and toxic megacolon. The oral route being compromised, the available treatments, which are mostly oral, have difficulty reaching the intestine because of the patient's pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously do not cross the gastrointestinal barrier and therefore do not reach the infection site. DNV3837 – a prodrug5 of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff. It has demonstrated significant activity and superiority to reference treatments against isolates of C. diff., regardless of their virulence (including the hyper virulent BI/NAP1/027 strain). DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approximately a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status.
공시 • Jan 07Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile InfectionsDEINOVE announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI). The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial. The experience acquired during this first part of the study has made it possible to improve the trial protocol, with a reduction in dose by a factor of 4 and a reduction in the duration of administration by a factor of 2, reducing the intravenous treatment from 12 to 6 hours per day. This improvement simplifies the management of the trial for the investigating physicians and their teams. The second part of the study will be conducted in an “open-label” manner, as DNV3837 is administered intravenously, while the standards of care are administered orally. Thus, all patients included in the trial (40 in total) will receive DNV3837. To improve patients inclusion in the trial, it was decided to rapidly open new centers in addition to those active in the United States.
Reported Earnings • Oct 03First half 2021 earnings releasedFirst half 2021 results: Net loss: €3.15m (loss narrowed 32% from 1H 2020).
Reported Earnings • Mar 27Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €836.0k (up 49% from FY 2019). Net loss: €7.30m (loss narrowed 29% from FY 2019).
공시 • Jan 22Deinove SA Appoints Hervé Ansanay as DirectorDeinove SA announces the strengthening of its Business Development team with the appointment of Hervé ANSANAY as Director and Corentin. The recruitment will intensify the implementation of profitable strategic partnerships and the access to non-dilutive financing, to support the development of antimicrobial therapeutic solutions. Hervé ANSANAY brings 20 years experience in accompanying innovative companies and in technology transfer. He was previously Technology Transfer and Business Development Director of the SATT AxLR of Montpellier where he also held the position of Chief Operating Officer.
Is New 90 Day High Low • Jan 05New 90-day high: €0.91The company is up 50% from its price of €0.61 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Nov 26New 90-day high: €0.73The company is up 7.0% from its price of €0.68 on 28 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.58 per share.
공시 • Nov 20Deinove SA Signs an Evaluation and Technology Development License with DSMDeinove SA announced the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living. Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.
Is New 90 Day High Low • Oct 26New 90-day low: €0.54The company is down 30% from its price of €0.77 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.
Reported Earnings • Oct 15First half earnings releasedOver the last 12 months the company has reported total losses of €9.52m, with losses narrowing by 8.2% from the prior year.